Evidence map›Paper›PMID 36197410›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

TP53 or Not TP53: That Is the Question.

Steven D Green, Joshua F Zeidner

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Steven D GreenRoswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1053-3364
Joshua F ZeidnerUniversity of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.ORCID 0000-0002-9014-1514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens. See related article by Pollyea et al., p. 5272.

Indexed as

AzacitidineLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicCytogenetic AnalysisHumansMutationSulfonamidesTumor Suppressor Protein p53AzacitidineBridged Bicyclo Compounds, HeterocyclicSulfonamidesTP53 protein, humanTumor Suppressor Protein p53venetoclax

Identifiers

PMID36197410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.